

# Chinese biopharma



**China is the global leader in innovation, out-licensing, and regulatory integration.**



**Out-licensing surged to \$50 billion in 2025, maintaining high growth rates.**



**66% of globally approved NASs secured marketing authorisation in China.**




**China is the global leader in targeted protein degradation research papers and patents.**

## Government support

Comprehensive "end-to-end innovation support" policies, including fast-track clinical trial approvals and the integration of commercial health insurance, have accelerated the development and commercialisation of innovative drugs.

## Projected annual growth (billion US \$)




## Unprecedented growth

Since 2022, Chinese biopharma out-licensing surged, reaching \$50 billion in 2025, 8% of global deals. With 35% annual growth and sought-after assets due to cost advantages and quality clinical data, China solidifies its global competitiveness, driving innovation and collaboration in the biopharma industry.



Projected to grow at 35% annually

## Projected market share in 2025



## TPD leadership

China leads in targeted protein degradation (TPD) technology, contributing 38% of global research papers, 37% of patents, and 30% of drug candidates by 2024.

This innovation addresses "undruggable" targets, earning global recognition and fostering biopharma collaboration.